Samjin Pharmaceutical삼진제약
005500 · KOSPI · ₩005500 · 삼진제약
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩24,591
vs the current price (₩19,310)
- Enterprise value
- ₩326B
- Equity value
- ₩328B
- WACC
- 7.2%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩13,793
- −28.6%
- Base
- ₩24,591
- +27.3%
- Bull
- ₩43,809
- +126.9%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (8.8%).
Revenue growth
- 4.1%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.
- 3.8%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.
- 3.5%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.
- 3.3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.
Business
- 8.8%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 3%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so a typical level.
- 4%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: not in the statements, so a typical level.
- 40%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.03%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-27.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.1, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.53%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩311B
- Net debt (borrowings and leases − cash and deposits)
- ₩8B
- + Stakes and investments
- ₩10B
- Associates, long-term financial assets and deposits (book value)
- Shares
- 13,320,000
- Share price
- ₩19,310
- Market cap
- ₩257B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩292B | ₩308B | ₩309B | ₩324B | ₩336B | ₩348B | ₩360B | ₩371B |
| Growth | 6.6% | 5.6% | 0.3% | 4.1% | 3.8% | 3.5% | 3.3% | 3.0% |
| EBIT | ₩20B | ₩32B | ₩27B | ₩29B | ₩30B | ₩31B | ₩32B | ₩33B |
| EBIT margin | 7.0% | 10.3% | 8.7% | 8.8% | 8.8% | 8.8% | 8.8% | 8.8% |
| After-tax EBIT | ₩15B | ₩23B | ₩19B | ₩21B | ₩21B | ₩22B | ₩23B | ₩24B |
| + Depreciation | — | — | — | ₩9.7B | ₩10B | ₩10B | ₩11B | ₩11B |
| − Capital spending | — | — | — | ₩13B | ₩13B | ₩14B | ₩14B | ₩15B |
| − Working capital | ₩25B | ₩5B | ₩21B | ₩5.1B | ₩4.9B | ₩4.7B | ₩4.6B | ₩4.3B |
| Free cash flow | — | — | — | ₩12B | ₩13B | ₩14B | ₩15B | ₩16B |
| Discount factor | — | — | — | 0.933 | 0.870 | 0.811 | 0.756 | 0.705 |
| Present value | — | — | — | ₩12B | ₩11B | ₩11B | ₩11B | ₩11B |
Terminal value ₩381B, worth ₩269B today: 83% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩22,430 a share)Now 0.86× | ₩19,1090.85× | ₩23,0001.03× | ₩32,3081.44× |
| Price / earnings (last 12 months: ₩1,642 a share)Now 11.8× | ₩9,9386.05× | ₩20,37412.4× | ₩31,60519.3× |
| P/E on run-rate earnings (Q2 2026 × 4: ₩1,413 a share)Now 13.7× | ₩8,5536.05× | ₩17,53412.4× | ₩27,19919.3× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.2% | ₩27,060 | ₩28,684 | ₩30,681 | ₩33,203 | ₩36,493 |
| 6.7% | ₩24,555 | ₩25,806 | ₩27,312 | ₩29,166 | ₩31,505 |
| 7.2% | ₩22,455 | ₩23,433 | ₩24,591 | ₩25,984 | ₩27,698 |
| 7.7% | ₩20,671 | ₩21,445 | ₩22,347 | ₩23,414 | ₩24,698 |
| 8.2% | ₩19,137 | ₩19,755 | ₩20,466 | ₩21,294 | ₩22,274 |
Now (TTM)
- Market cap
- ₩257B
- Enterprise value
- ₩264B
- P/E
- 11.8×
- P/B
- 0.9×
- P/S
- 0.8×
- EV/EBITDA
- —
- Dividend yield
- 4.1%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩19,750 | ₩18,070 | ₩21,600 | ₩25,650 | ₩26,300 |
| Market cap | ₩263B | ₩241B | ₩288B | ₩342B | ₩350B |
| P/E | 10.9× | 6.1× | 15.2× | 16.2× | 12.3× |
| P/B | 0.9× | 0.9× | 1.1× | 1.2× | 1.5× |
| P/S | 0.9× | 0.8× | 1.0× | 1.2× | 1.4× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 4.1% | 4.4% | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Samjin Pharmaceutical | 11.8× | 0.9× | 0.8× | — | 4.1% |
| Samsung Biologics | 32.1× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.8× | 2.4× | 8.9× | — | 0.0% |
| Alteogen | 78.8× | 28.4× | 59.9× | — | 0.1% |
| Yuhan | 24.8× | 2.5× | 2.6× | 32.5× | 0.8% |
| SK biopharmaceuticals | 14.6× | 5.7× | 6.8× | — | 0.0% |
| HLB | — | 15.4× | 54.6× | — | 0.0% |
| Similar companies (median) | 27.8× | 6.7× | 11.5× | 32.5× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Samjin Pharmaceutical / 삼진제약 / 005500 / KRX:005500
Source: KRX statistical information